Radioresistance and immune escape are crucial reasons for unsatisfactory therapeutic effects of glioblastoma (GBM). Although triggering receptor expressed on myeloid cells-2 (TREM2) involved in forming immunos... Hui Qiu, Zhiying Shao, Xin Wen, Debao Qu, Zhengyang Liu, Ziqin Chen, Xinyan Zhang, ...
Rancoule C, Vallard A, Espenel S, Guy JB, Xia Y, El Meddeb HA, Rodriguez-Lafrasse C, Chargari C, Deutsch E, Magne N. Immunotherapy in head and neck cancer: harnessing profit on a system disruption. Oral Oncol. 2016;62(1):53–62. Google Scholar Dou R, Nishihara R, Cao Y, ...
CD38-Mediated immunosuppression as a mechanism of Tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018;8(9):1156–75. Article CAS PubMed PubMed Central Google Scholar Wang T-F, Guidotti G. CD39 is an Ecto-(Ca2+,Mg2+)-apyrase. J Biol Chem. 1996;271(17):9898–901. ...
tumor cells has also recently been elucidated [67]. Indeed, interfaces between PD-L1 on tumor cells with PD-1 on immune cells sustain immune escape and tumor development more chiefly by suppression of cytotoxic T lymphocyte (CTL) effector function [68]. Improved expression of PD-L1 on tumors ...
We thank E. Deutsch (GRCC) for critical reading. A.M. gratefully acknowledges financial support from BMS, Fondation MSD Avenir, INSERM CIC 1428 Biotherapies, the Institut National du Cancer (INCa) and the SIRIC Stratified Oncology Cell DNA Repair and Tumour Immune Elimination (SOCRATE). G.K....
dosing schedules and accurate timing of each combination partner need to be respected to prevent immune escape and resistance. In this review, we provide a detailed summary of CDK inhibitors in the two solid cancer types head and neck cancer and glioblastoma multiforme; it describes the molecular ...
Deutsch, T.L. Lenz, S. Onengut-Gumuscu, B. Han, W.-M. Chen, J.M. Howson, J.A. Todd, P.I. de Bakker, S.S. Rich, S. Raychaudhuri Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk Nat. Genet, 47 (...
Restriction of both the effector and regulatory T‑cell populations to an oligoclonal repertoire would reduce the overlap between regulatory and effector T‑cell specificities, facilitating the escape of autoreactive oligoclonal effector T cells (FIG. 4b). This principle has been demonstrated ...
However, tumor cells can escape immune surveillance and inhibit antitumor effects through immune checkpoint pathways, ultimately weakening the immune response [[1], [2], [3]]. Multiple strategies targeting these processes, especially immune checkpoint inhibitors (ICIs), have achieved great success. ...
Although PD-1 is vital for limiting autoimmunity and regulating immune tolerance, it is also associated with tumor escape [46]. PD-L1 is overexpressed in various tumor cells due to the activation of intrinsic oncogenic pathways or specific inflammatory signals and evades immune attack [47], [48...